Year-over-year revenue increased 80% for the fiscal third quarter and 193% for the nine months ended March 31, 2024 Cash and cash equivalents as of March 31, 2024, was $9.40 million Commenced FDA 510(k) clinical studies plan with Cliantha Research and remains on track for planned submission by the end of 2024 and planned entry into the US in 2025 Secured 26 new customer accounts throughout the quarter, representing a combined headcount of approximately 16,779 employees NEW YORK, May 08, 2024 (GLOBE NEWSWIRE ...

NEW YORK, April 11, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. ("INBS" or the "Company") (NASDAQ:INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the broadening of the intellectual property portfolio of its wholly owned subsidiary, Intelligent Fingerprinting Limited, with the grant of a new European patent with unitary effect for its ground-breaking DSR-Plus Cartridge Reader. This latest achievement follows the successful protect ...

Revenue and Sales Performance - Revenue for the three months ended December 31, 2023, was $764,063, a significant increase from $356,679 in the same period of 2022, representing a growth of 114%[158] - Revenue from sales of goods increased by $407,385 from $356,679 to $764,064 for the quarter ended December 31, 2023, compared to the same period in 2022, driven by customer base expansion[159] - Revenue from sales of goods increased by $1,203,478 from $356,679 to $1,560,157 for the six months ended December 31, 2023, compared to the same period in 2022, attributed to the acquisition of IFP[160] Profit and Loss - Gross profit for the three months ended December 31, 2023, was $199,248, compared to $244,044 in the same period of 2022, indicating a decrease of 18%[158] - The company reported a net loss of $1,976,383 for the three months ended December 31, 2023, compared to a net loss of $427,071 in the same period of 2022, reflecting an increase in losses of 363%[158] - Net loss attributable to INBS increased by $1,549,041 from $420,600 to $1,969,641 for the quarter ended December 31, 2023, compared to the same period in 2022[185] Operating Expenses - Operating expenses for the three months ended December 31, 2023, totaled $2,343,809, a decrease from $2,644,636 in the same period of 2022, showing a reduction of 11%[158] - Selling, general and administrative expenses decreased by $540,245 to $1,705,044 from $2,245,289 for the quarter ended December 31, 2023, compared to the same period in 2022[168] - Development and regulatory approval expenses increased by $347,261 from $1,191 to $348,452 for the quarter ended December 31, 2023, compared to the same period in 2022[171] Financial Position - Cash and cash equivalents as of December 31, 2023, were $1,119,004, with a working capital deficit of $2,238,430[188] - The company raised approximately $4.38 million through a public offering on October 4, 2023, with net proceeds of approximately $3.79 million to fund ongoing operations[154] - The Company raised approximately $4.38 million through a registered underwritten public offering on October 4, 2023, with net proceeds of approximately $3.79 million[190] Market Expansion and Product Development - The company expanded into the New Zealand market on October 24, 2023, enhancing its global footprint for drug screening products[155] - The company completed 25,000 Intelligent Fingerprinting tests during the quarter, demonstrating growing demand for its drug screening products across various industries[157] - The National Association of Testing Authorities (NATA) accredited the company's laboratory partner for fingerprint confirmatory drug testing, enhancing product quality and reliability[157] Other Financial Metrics - The weighted average shares outstanding for the three months ended December 31, 2023, was 949,660, compared to 75,690 in the same period of 2022, reflecting a significant increase due to stock splits[158] - The company reported a fair value gain on revaluation of financial instruments of $44,488 for the three months ended December 31, 2023, compared to a gain of $1,793,091 in the same period of 2022[158] - Cost of revenue increased by $452,180 from $112,635 to $564,815 for the quarter ended December 31, 2023, compared to the same period in 2022, in line with business growth[161] - Gross profit decreased by $44,796 from $244,044 to $199,248 for the quarter ended December 31, 2023, compared to the same period in 2022, due to increased direct costs[163] - Government support income decreased by $116,421 from $269,625 to $153,204 for the quarter ended December 31, 2023, compared to the same period in 2022[165]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number 001-39825 Intelligent Bio Solutions Inc. (Exact name of Registrant as specified in its Charter) Delaware 82-1512711 ...

As filed with the Securities and Exchange Commission on September 28, 2023 Registration No. 333-273219 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 5 TO Form S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INTELLIGENT BIO SOLUTIONS INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of (Primary Standard Industrial (I.R.S. Employer incorporation or organization) Classification Code Number) Identification Number) Delawar ...

As filed with the Securities and Exchange Commission on September 22, 2023 Registration No. 333-273219 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 4 142 West 57 Street, 11Floor New York, New York 10019 Telephone: (646) 828-8258 TO Form S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INTELLIGENT BIO SOLUTIONS INC. (Exact name of registrant as specified in its charter) Delaware 3829 82-1512711 (State or other jurisdiction of (Primary Standard Industrial (I ...

As filed with the Securities and Exchange Commission on September 11, 2023 Registration No. 333-273219 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INTELLIGENT BIO SOLUTIONS INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of (Primary Standard Industrial (I.R.S. Employer incorporation or organization) Classification Code Number) Identification Number) Delaware 3829 82-1512711 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT ...

As filed with the Securities and Exchange Commission on September 5, 2023 Registration No. 333-273219 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 TO Form S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INTELLIGENT BIO SOLUTIONS INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of (Primary Standard Industrial (I.R.S. Employer incorporation or organization) Classification Code Number) Identification Number) Delaware ...

Revenue and Profit - Revenue for the year ended June 30, 2023, was $1,256,872, an increase from $0 in the previous year, attributed to the acquisition of Intelligent Fingerprinting Limited and the launch of fingerprint drug testing in the APAC region [317]. - Gross profit for the same period was $326,668, up from $0, primarily due to the acquisition of Intelligent Fingerprinting Limited [320]. - Government support income rose to $737,628 from $437,146, an increase of $300,482, mainly due to qualifying research and development expenditures [322]. - Fair value gain on revaluation of financial instruments increased by $2,154,365 to $2,154,365 from $0 for the year ended June 30, 2023 [332]. - Interest income decreased by $4,750 to $9,676 from $14,426 for the year ended June 30, 2023, due to lower bank balance [333]. - Unrealized foreign currency translation gain increased by $339,514 to a gain of $212,639 from a loss of $126,875 for the year ended June 30, 2023 [334]. - Net loss attributable to INBS increased by $2,325,669 to $10,631,720 from $8,306,051 for the year ended June 30, 2023, primarily driven by impairment of goodwill of $4,158,670 [335]. Expenses - Selling, general and administrative expenses increased by $3,106,600 to $8,026,703, largely due to the addition of approximately 32 staff from the acquisition of Intelligent Fingerprinting Limited [324]. - Development and regulatory expenses decreased by $3,346,495 to $507,424, primarily due to the expensing of a prepaid R&D contribution in the previous year [326]. - Depreciation and amortization expenses were $966,732, an increase from $0, due to the amortization of acquired intangibles from the acquisition [328]. - Goodwill impairment expenses were $4,158,670, reflecting the impact of the acquisition of Intelligent Fingerprinting Limited [329]. - Interest expense increased to $223,534 from $7,539, attributed to interest on convertible notes post-acquisition [330]. Cash and Working Capital - As of June 30, 2023, the company had $1,537,244 in cash and cash equivalents and a working capital deficit of $2,021,124 [337]. - The company expects its cash and cash equivalents will be insufficient to fund its current operating plan for at least the next twelve months [338]. Grants and Deferred Income - The total grant value of $4.7 million was recognized as both a grant receivable and deferred grant income, with payments of $1.4 million and $2.1 million received during the years ended June 30, 2023 and 2022, respectively [348]. - A total of $127,944 and $51,258 deferred grant income was recognized within other income during the years ended June 30, 2023, and 2022, respectively [350]. Strategic Initiatives - The company intends to submit a 510(k) pre-market notification for its Intelligent Fingerprinting Drug Screening Cartridge as part of its U.S. expansion strategy [315]. - The company has expanded its customer base by entering into sales contracts with various firms, enhancing its market presence [316]. Other Information - The company has no off-balance sheet arrangements or relationships with unconsolidated entities [341]. - The company recognized an impairment charge of $4.2 million in the IFPG segment related to goodwill associated with the IFP Acquisition [354].

As filed with the Securities and Exchange Commission on July 27, 2023 Registration No. 333-273219 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO Form S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INTELLIGENT BIO SOLUTIONS INC. (Exact name of registrant as specified in its charter) 142 West 57 Street, 11Floor New York, New York 10019 Telephone: (646) 828-8258 (Address, including zip code, and telephone number, including area code, of registrant's prin ...